Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golvatinib + Sorafenib vs Sorafenib in HCC
NCT01271504Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Jul 2011
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, open-label trial of Golvatinib in hepatocellular carcinoma (HCC) (3 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Dose Limiting Toxicity, Maximum Observed Plasma Concentration and 4 more. Started Jul 2011; status: completed.
02
Drugs
Golvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01271504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01271504.